NCT04966663

Using ctDNA to Determine Therapies for Lung Cancer

From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Detailed description

For people who have early stage non-small cell lung cancer (NSCLC), the usual treatment is surgery. For many people, surgery is enough to get rid of all the cancer. However, for some people, there may be a little bit of cancer remaining. If there is some cancer left over, it may lead to the cancer regrowing. This is called relapse. Many cancers shed little bits of their DNA (deoxyribonucleic acid, molecules that contain instructions for how cells develop and function) into the bloodstream. A blood test can be used to test for the amount of circulating tumour DNA (ctDNA). Some studies have shown that the presence of ctDNA in the blood may predict cancer recurrence. The purpose of this research study is to see if adjuvant treatment (additional treatment given after primary treatment) can help decrease the risk of the cancer recurring in people with lung cancer who have ctDNA detected in their blood after surgery.

Conditions

• Non Small Cell Lung Cancer
• Complete Surgical Resection
• Circulating Tumor DNA

Interventions

Type	Name	Description
DRUG	Nivolumab	Antineoplastic agent
DRUG	Pemetrexed	Antineoplastic agent
DRUG	Gemcitabine	Antineoplastic agent
DRUG	Cisplatin	Antineoplastic agent
DRUG	Carboplatin	Antineoplastic agent
PROCEDURE	ctDNA blood test	Blood will be collected for ctDNA testing

Timeline

• Start date: 2022-03-28
• Primary completion: 2026-08-01
• Completion: 2026-12-01
• First posted: 2021-07-19
• Last updated: 2025-12-18

Locations

1 site across 1 country: Canada